Cargando…
Letter to the Editor: Comment on “Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth”
Autores principales: | Peckham, Alyssa M., Covvey, Jordan R., Evoy, Kirk E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119553/ https://www.ncbi.nlm.nih.gov/pubmed/33565039 http://dx.doi.org/10.1007/s40122-020-00222-z |
Ejemplares similares
-
Response to Comment on “Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth”
por: McAnally, Heath B., et al.
Publicado: (2021) -
Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
por: McAnally, Heath, et al.
Publicado: (2020) -
Correction to: Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
por: McAnally, Heath, et al.
Publicado: (2020) -
Reply to Letter to the Editor Regarding Article: “Considering the Potential Benefits of Over-The-Counter Naloxone” [Response To Letter]
por: Evoy, Kirk E, et al.
Publicado: (2021) -
Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids
por: Desai, Payal H., et al.
Publicado: (2021)